ly2510924
Peptideexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2011 (NCT01391130)
Timeline
Indications
Mechanism of action
- C-X-C chemokine receptor type 4INHIBITOR
CXCR4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ly2510924
- ly2510924
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02737072 | Phase 1 | Sep 1, 2016 | AstraZeneca, Eli Lilly |
| NCT02652871 | Phase 1 | May 1, 2016 | Eli Lilly, High Impact Clinical Research Support Program, University of Texas at Houston |
| NCT01439568 | Phase 2 | Sep 1, 2011 | Eli Lilly |
| NCT01391130 | Phase 2 | Aug 1, 2011 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 3 | 2 | 2011 |
| AstraZeneca | For profit | 1 | 0 | 1 | 2016 |
| High Impact Clinical Research Support Program | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2016 |
4 organizations
Page 1 / 1